Keyword: Germany

A new $100 million (€85 million) capital fund out of Germany has closed and is looking for “ground-breaking” heart disease tech.

Immunic licensed an inflammatory bowel disease program from Daiichi Sankyo and is preparing to bring it into phase 1.

Two research teams are proposing new methods for killing drug-resistant bacteria by taking advantage of structural weaknesses.

Researchers have developed software that reconstructs tissue slides into a navigable, 3D organ model that can illustrate cellular functions.

The fund sets Wellington up to invest in 15 to 20 drug development and medical device companies.

German pharma Boehringer Ingelheim is putting a few hundred million euros on the table to snap up Swiss cancer biotech Amal Therapeutics.

The series B positions the immuno-oncology player to advance its multidrug clinical pipeline and grow its manufacturing footprint. 

The German biotech will use the €12 million to take a small molecule treatment for parkinsonian disorders into the clinic.

Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion in 2018 for up to $1.2 billion.

The job losses are part of Sanofi's pivot away from cardiovascular diseases and toward immuno-oncology drugs and gene therapies.